Trials / Withdrawn
WithdrawnNCT05057273
Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- NImmune Biopharma · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2, randomized, double-blind, multicenter study to assess the therapeutic efficacy, safety, and mechanisms of omilancor (BT-11) in patients with moderate to severe Crohn's Disease (CD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BT-11 | Oral once daily tablet |
| DRUG | Active comparator | Biologic |
Timeline
- Start date
- 2021-11-01
- Primary completion
- 2022-02-01
- Completion
- 2022-02-01
- First posted
- 2021-09-27
- Last updated
- 2023-06-07
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05057273. Inclusion in this directory is not an endorsement.